The Microbiome: A Frontline Barrier and Emerging Ally in Cancer Treatment
/in Clinical Trial, Not PCa related/by MaxBR111: A New ADC Therapy That Could Work Also For Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxPioneering Korean Trial Combines Radioligand Therapy and Immunotherapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Clinical Trial Recruiting: HLD-0915 a RIPTAC (Regulated Induced Proximity Targeting Chimera)
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Will Soon Start Recruiting: ACE-232 a Promising Inhibitor of CYP11A1
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CRB-701, A Promising Antibody-Drug Conjugate Targeting Nectin-4
/in Clinical Trial, Metastatic, Phase 1/by MaxLY4052031 and LY4101174: Other 2 Nectin-4-Targeting Therapy
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Newsletter 12/2026 March 22, 2026
- JMKX007129: A Next‑Generation AR‑NTD Inhibitor for Overcoming Resistance in mCRPC March 20, 2026
- AUTOTAC Degraders ATB‑238 and ATB‑239 Target AR and AR‑v7 in Advanced Prostate Cancer March 20, 2026
- ²²⁵Ac‑RAX104: A Next‑Generation PSMA Alpha Radioligand for Advanced Prostate Cancer March 20, 2026